"The voice for cancer physicians and their patients in Massachusetts."

FDA has approved a new indication for IMFINZI® (durvalumab), in combination with IMJUDO® (tremelimumab-actl), for unresectable HCC

24 Oct 2022 10:14 AM | Katy Monaco (Administrator)

Food and Drug Administration approved IMJUDO® (tremelimumab-actl), (AstraZeneca Pharmaceuticals) in combination with IMFINZI® (durvalumab) for adult patients with unresectable hepatocellular carcinoma (uHCC). Read More. 

Please see Full Prescribing Information including Medication Guide for IMFINZI and IMJUDOYou may report side effects related to AstraZeneca products by clicking here.

Massachusetts Society of Clinical Oncologists ©2022

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  Fax: 781.464.4896  |  email: msco@mms.org

Powered by Wild Apricot Membership Software